Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effect of pembrolizumab and simultaneous radiotherapy in patients with advanced melanoma in the French early access program

Trial Profile

Effect of pembrolizumab and simultaneous radiotherapy in patients with advanced melanoma in the French early access program

Status: Completed
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 22 Jun 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Malignant melanoma
  • Focus Expanded access; Therapeutic Use
  • Acronyms HORIZON
  • Most Recent Events

    • 22 Jun 2018 New trial record
    • 05 Jun 2018 Results assessing the outcomes of pembrolizumab treatment in elderly melanoma patients (n=160) presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 05 Jun 2018 Results (n=125) assessing the impact of simultaneous radiotherapy in melanoma patients treated with pembrolizumab, presented at the 54th Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top